FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the pharmaceutical industry and represents an ophthalmic solution containing riboflavin and vitamin E for the UV-A rays protection of the internal structures of an eyeball and for treating keratoconus by transepithelial crosslinking.
EFFECT: invention provides extending the range of products for the UV-A rays protection of the internal structures of the eyeball and for treating keratoconus by transepithelial crosslinking.
9 cl, 10 dwg
Title | Year | Author | Number |
---|---|---|---|
STAINING SUBSTANCE FOR DIAGNOSTIC OPHTHALMIC APPLICATION | 2013 |
|
RU2639915C2 |
OPHTHALMIC AGENT FOR TRANSEPITHELIAL ULTRAVIOLET CORNEAL COLLAGEN CROSSLINKING | 2014 |
|
RU2560669C1 |
OPHTHALMIC COMPOSITIONS OF TAMARIND SEED POLYSACCHARIDE AND HYALURONIC ACID | 2008 |
|
RU2493855C2 |
OPHTHALMOLOGICAL MEANS FOR ULTRAVIOLET CORNEAL CROSSLINKING | 2016 |
|
RU2646452C1 |
METHOD OF TREATING KERATOCONUS STAGE I-II | 2022 |
|
RU2819801C2 |
METHOD OF TREATMENT OF KERATECTASIA BY THE METHOD OF PULSE ACCELERATED ULTRAVIOLET CROSSLINKING OF CORNEA | 2017 |
|
RU2682494C1 |
HYPOSMOTIC OPHTHALMIC MEANS FOR ULTRAVIOLET CROSSLINKING OF THIN CORNEAS | 2016 |
|
RU2631604C1 |
CORNEAL CROSSLINKING METHOD | 2021 |
|
RU2822101C2 |
METHOD FOR CORNEAL COLLAGEN CROSSLINKING IN KERATECTASIAS OF VARIOUS GENESIS | 2021 |
|
RU2778968C1 |
KERATECTASIAS TREATMENT METHOD | 2017 |
|
RU2645931C1 |
Authors
Dates
2015-02-10—Published
2010-07-23—Filed